Inovio Pharmaceuticals stock (US45773H2013): Q1 2026 results and INO-3107 FDA review

Inovio Pharmaceuticals reported Q1 2026 net loss of $19.7M, beat EPS estimates, while FDA reviews BLA for INO-3107 with PDUFA target Oct 30, 2026. Cash runway into Q1 2027.

Inovio Pharmaceuticals released its first quarter 2026 financial results on May 13, 2026, reporting a net loss of $19.7 million, or $0.28 per share, beating analyst EPS estimates of -$0.36. Revenue was $0 against expectations of $0.25 million. The FDA is actively reviewing the Biologics License Application (BLA) for INO-3107 under accelerated approval for recurrent respiratory papillomatosis (RRP), with a target PDUFA date of October 30, 2026, INOVIO IR as of 05/13/2026. Operating expenses dropped 12.6% year-over-year to $21.9 million.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Inovio Pharmaceuticals, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, global clinical trials
• Key revenue drivers: DNA medicines, immunotherapy products
• Home exchange/listing venue: Nasdaq (INO)
• Trading currency: USD

Inovio Pharmaceuticals: core business model

Inovio Pharmaceuticals develops DNA medicines using proprietary DNA delivery technology for vaccines and immunotherapies targeting cancers and infectious diseases. The platform uses electroporation to deliver DNA plasmids directly into cells, triggering immune responses. INO-3107, a lead candidate, targets recurrent respiratory papillomatosis caused by HPV, StockTitan as of 05/13/2026. The company has advanced multiple assets through clinical stages, with commercialization preparations underway for potential approvals.

Cash and short-term investments stood at $37.7 million as of March 31, 2026, bolstered by $16 million net proceeds from an April 2026 public equity offering. This provides a runway into Q1 2027, past the INO-3107 PDUFA date, according to the Q1 report published May 13, 2026, INOVIO IR as of 05/13/2026.

Main revenue and product drivers for Inovio Pharmaceuticals

INO-3107 remains the primary focus, with BLA under FDA accelerated review for RRP in adults. Commercial readiness plans are advancing ahead of a potential 2026 launch. The company also announced a clinical trial collaboration with Akeso Inc. for INO-5412 combined with cadonilimab in a glioblastoma trial sponsored by Dana-Farber Cancer Institute, per the May 13, 2026 press release.

Historical revenue has been limited as Inovio prioritizes pipeline advancement over commercialization. Q1 2026 showed no revenue, consistent with clinical-stage biotech profiles. Future drivers hinge on INO-3107 approval and partnerships for other assets like INO-5412.

Industry trends and competitive position

The DNA medicine sector sees growing interest in precision immunotherapies for HPV-related diseases and cancers. Inovio's electroporation technology differentiates it from mRNA or viral vector approaches. RRP affects thousands annually in the US, creating a niche market for INO-3107 if approved.

Why Inovio Pharmaceuticals matters for US investors

Listed on Nasdaq as INO, Inovio offers US investors exposure to biotech innovation in immunotherapy. The FDA PDUFA for INO-3107 in October 2026 represents a key binary event. With cash supporting operations through this period, it aligns with US market focus on clinical milestones.

Conclusion

Inovio Pharmaceuticals' Q1 2026 results highlight financial discipline with reduced expenses and extended cash runway amid FDA review of INO-3107. The PDUFA target in October 2026 looms as a pivotal catalyst. Investors track commercialization progress and pipeline partnerships for future value inflection.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.